Seasonal transmission potential and activity peaks of the new influenza A(H1N1): a Monte Carlo likelihood analysis based on human mobility
- Duygu Balcan†1, 2,
- Hao Hu†1, 2, 3,
- Bruno Goncalves†1, 2,
- Paolo Bajardi†4, 5,
- Chiara Poletto†4,
- Jose J Ramasco4,
- Daniela Paolotti4,
- Nicola Perra1, 6, 7,
- Michele Tizzoni4, 8,
- Wouter Van den Broeck4,
- Vittoria Colizza4 and
- Alessandro Vespignani1, 2, 4Email author
DOI: 10.1186/1741-7015-7-45
© Balcan et al; licensee BioMed Central Ltd. 2009
Received: 31 July 2009
Accepted: 10 September 2009
Published: 10 September 2009
Abstract
Background
On 11 June the World Health Organization officially raised the phase of pandemic alert (with regard to the new H1N1 influenza strain) to level 6. As of 19 July, 137,232 cases of the H1N1 influenza strain have been officially confirmed in 142 different countries, and the pandemic unfolding in the Southern hemisphere is now under scrutiny to gain insights about the next winter wave in the Northern hemisphere. A major challenge is pre-empted by the need to estimate the transmission potential of the virus and to assess its dependence on seasonality aspects in order to be able to use numerical models capable of projecting the spatiotemporal pattern of the pandemic.
Methods
In the present work, we use a global structured metapopulation model integrating mobility and transportation data worldwide. The model considers data on 3,362 subpopulations in 220 different countries and individual mobility across them. The model generates stochastic realizations of the epidemic evolution worldwide considering 6 billion individuals, from which we can gather information such as prevalence, morbidity, number of secondary cases and number and date of imported cases for each subpopulation, all with a time resolution of 1 day. In order to estimate the transmission potential and the relevant model parameters we used the data on the chronology of the 2009 novel influenza A(H1N1). The method is based on the maximum likelihood analysis of the arrival time distribution generated by the model in 12 countries seeded by Mexico by using 1 million computationally simulated epidemics. An extended chronology including 93 countries worldwide seeded before 18 June was used to ascertain the seasonality effects.
Results
We found the best estimate R 0 = 1.75 (95% confidence interval (CI) 1.64 to 1.88) for the basic reproductive number. Correlation analysis allows the selection of the most probable seasonal behavior based on the observed pattern, leading to the identification of plausible scenarios for the future unfolding of the pandemic and the estimate of pandemic activity peaks in the different hemispheres. We provide estimates for the number of hospitalizations and the attack rate for the next wave as well as an extensive sensitivity analysis on the disease parameter values. We also studied the effect of systematic therapeutic use of antiviral drugs on the epidemic timeline.
Conclusion
The analysis shows the potential for an early epidemic peak occurring in October/November in the Northern hemisphere, likely before large-scale vaccination campaigns could be carried out. The baseline results refer to a worst-case scenario in which additional mitigation policies are not considered. We suggest that the planning of additional mitigation policies such as systematic antiviral treatments might be the key to delay the activity peak in order to restore the effectiveness of the vaccination programs.
Background
Estimating the transmission potential of a newly emerging virus is crucial when planning for adequate public health interventions to mitigate its spread and impact, and to forecast the expected epidemic scenarios through sophisticate computational approaches [1–4]. With the current outbreak of the new influenza A(H1N1) strain having reached pandemic proportions, the investigation of the influenza situation worldwide might provide the key to the understanding of the transmissibility observed in different regions and to the characterization of possible seasonal behavior. During the early phase of an outbreak, this task is hampered by inaccuracies and incompleteness of available information. Reporting is constrained by the difficulties in confirming large numbers of cases through specific tests and serological analysis. The cocirculation of multiple strains, the presence of asymptomatic cases that go undetected, the impossibility to monitor mild cases that do not seek health care and the possible delays in diagnosis and reporting, all worsen the situation. Early modeling approaches and statistical analysis show that the number of confirmed cases by the Mexican authorities during the early phase was underestimated by a factor ranging from one order of magnitude [5] to almost three [6]. The Centers for Disease Control (CDC) in the US estimate a 5% to 10% case detection, similar to other countries facing large outbreaks, with expected heterogeneities due to different surveillance systems. Even within the same country, the setup of enhanced monitoring led to improved notification with respect to the earlier phase of the pandemic, later relaxed as reporting requirements changed [7].
By contrast, the effort put in place by the World Health Organization (WHO) and health protection agencies worldwide is providing an unprecedented amount of data and, at last, the possibility of following in real time the pandemic chronology on the global scale. In particular, the border controls and the enhanced surveillance aimed at detecting the first cases reaching uninfected countries appear to provide more reliable and timely information with respect to the raw count of cases as local transmission occurs, and this data has already been used for early assessment of the number of cases in Mexico [5]. Moreover, data on international passenger flows from Mexico was found to display a strong correlation with confirmed H1N1 importations from Mexico [8]. Here we present an estimate of the reproduction number, R 0, (that is, the average number of secondary cases produced by a primary case [9]) of the current H1N1 epidemic based on knowledge of human mobility patterns. We use the GLEaM (for GLobal Epidemic and Mobility) structured metapopulation model [10] for the worldwide evolution of the pandemic and perform a maximum likelihood analysis of the parameters against the actual chronology of newly infected countries. The method is computationally intensive as it involves a Monte Carlo generation of the distribution of arrival time of the infection in each country based on the analysis of 106 worldwide simulations of the pandemic evolution with the GLEaM model. The method shifts the burden of estimating the disease transmissibility from the incidence data, suffering notification/surveillance biases and dependent on country specific surveillance systems, to the more accurate data of the early case detection in newly affected countries. This is achieved through the modeling of human mobility patterns on the global level obtained from high quality databases. In other words, the chronology of the infection of new countries is determined by two factors. The first is the number of cases generated by the epidemic in the originating country. The second is the mobility of people from this country to the rest of the world. The mobility data are defined from the outset with great accuracy and we can therefore find the parameters of the disease spreading as those that provide the best fit for the time of infection of new countries. This method also allows for uncovering the presence of a seasonal signature in the observed pattern, not hindered or effectively caused by notification and reporting changes in each country's influenza monitoring. The obtained values for the reproduction numbers are larger than the early estimates [5], though aligned with later works [11–13]. The simulated geographic and temporal evolution of the pandemic based on these estimates shows the possibility of an early epidemic activity peak in the Northern hemisphere as soon as mid October. While the simulations refer to a worst-case scenario, with no intervention implemented, the present findings pertain to the timing of the vaccination campaigns as planned by many countries. For this reason we also present an analysis of scenarios in which the systematic use of antiviral drug therapy is implemented with varying effectiveness, according to the national stockpiles, and study their effect on the epidemic timeline.
Methods
Schematic illustration of the GLobal Epidemic and Mobility (GLEaM) model. Top: census and mobility layers that define the subpopulations and the various types of mobility among those (commuting patterns and air travel flows). The same resolution is used worldwide. Bottom: compartmental structure in each subpopulation. A susceptible individual in contact with a symptomatic or asymptomatic infectious person contracts the infection at rate β or r ββ [30, 32], respectively, and enters the latent compartment where he is infected but not yet infectious. At the end of the latency period, each latent individual becomes infectious, entering the symptomatic compartments with probability 1 - p a or becoming asymptomatic with probability p a [30, 32]. The symptomatic cases are further divided between those who are allowed to travel (with probability p t) and those who would stop traveling when ill (with probability 1 - p t) [30]. Infectious individuals recover permanently with rate μ. All transition processes are modeled through multinomial processes.
Illustration of the model's initialization and the results for the activity peaks in three geographical areas. (a) Intensity of the commuting between US and Mexico at the border of the two countries. (b) The 12 countries infected from Mexico used in the Monte Carlo likelihood analysis. The color scale of the arrows from red to yellow indicates the time ordering of the epidemic invasion. Panels (c), (d) and (e) show the daily incidence in Lower South America, South Pacific and North America/Western Europe, respectively. The shaded area indicates the 95% confidence interval (CI) of the peak time in the corresponding geographical region. The median incidence profiles of selected countries are shown for the two values defining the best-fit seasonality scaling factor interval.
In order to ascertain the effect of seasonality on the observed pattern, we explored different seasonality schemes. The seasonality is modeled by a standard forcing that rescales the value of the basic reproductive number into a seasonally rescaled reproductive number, R(t), depending on time. The seasonal rescaling is time and location dependent by means of a scaling multiplicative factor generated by a sinusoidal function with a total period of 12 months oscillating in the range αmin to αmax, with αmax = 1.1 days (sensitivity analysis in the range 1.0 to 1.1) and αmin a free parameter to be estimated [17]. The rescaling function is in opposition in the Northern and Southern hemispheres (see Additional file 1 for details). No rescaling is assumed in the Tropics. The value of R 0 reported in the Tables and the definition of the baseline is the reference value in the Tropics. In each subpopulation the R(t) relative to the corresponding geographical location and time of the year is used in the simulations.
Best Estimates of the epidemiological parameters
Parameter | Best Estimate | Interval estimate(a) | Description |
|---|---|---|---|
R 0 | 1.75 | 1.64 to 1.88 | Basic reproduction number |
G t | 3.6 | 2.2 to 5.1 | Mean generation time (days) |
μ-1 | 2.5 | 1.1 to 4.0 | Mean infectious period (days) |
αmin | 0.65 | 0.6 to 0.7 | Minimal seasonality rescaling |
Assumed values: | |||
Assumed value at best estimate | Sensitivity analysis range | ||
ε-1 | 1.1 | 1.1 to 2.5 | Mean exposed period (days) |
αmax | 1.1 | 1.0 to 1.1 | Maximum seasonality rescaling |
The major problem in the case of projections on an extended time horizon is the seasonality effect that in the long run is crucial in determining the peak of the epidemic. In order to quantify the degree of seasonality observed in the current epidemic, we estimate the minimum seasonality scaling factor αmin of the sinusoidal forcing by extending the chronology under study and analyzing the whole data set composed of the arrival dates of the first infected case in the 93 countries affected by the outbreak as of 18 June. We studied the correlation between the simulated arrival time by country and its corresponding empirical value, by measuring the regression coefficient between the two datasets. Given the extended time frame under observation, the arrival times considered in this case are expected to provide a signature of the presence of seasonality. They included the seeding of new countries from outbreaks taking place in regions where seasonal effects might occur, as for example in the US or in the UK. For the simulated arrival times we have considered the median and 95% confidence interval (CI) emerging from the 2 × 103 stochastic runs. The regression coefficient is found to be sensitive to variations in the seasonality scaling factor, allowing discrimination of the αmin value that best fits the real epidemic. A detailed presentation of this analysis is reported in Additional file 1. The full exploration of the phase space of epidemic parameters and seasonality scenarios reported in Additional file 1 required data from 106 simulations; the equivalent of 2 million minutes of PowerPC 970 2.5 GHz CPU time.
Results and Discussion
Table 1 reports the results of the maximum likelihood procedure and of the correlation analysis on the arrival times for the estimation of αmin. In the following we consider as the baseline case the set of parameters defined by the best estimates: G t = 3.6 days, μ-1 = 2.5 days, R 0 = 1.75.
Seasonality time-dependent reproduction number in the Northern hemisphere
Month | R(t) in Northern hemisphere |
|---|---|
May | 1.19 to 1.49 |
June | 1.07 to 1.33 |
July | 1.05 to 1.24 |
August | 1.07 to 1.33 |
September | 1.19 to 1.49 |
The empirical arrival time data used for the likelihood analysis are necessarily an overestimation of the actual date of the importation of cases as cases could go undetected. If we assume a shift of 7 days earlier for all arrival times available from official reports, the resulting maximum likelihood is increasing the best estimate for R 0 to 1.87 (95% CI 1.73 to 2.01), as expected since earlier case importation necessitates a larger growth rate of the epidemic. The official timeline used here therefore provides, all other parameters being equal, a lower estimate of the transmission potential. We have also explored the use of a subset of the 12 countries, always generating results within the confidence interval of the best estimate.
The best estimates reported in Table 1 do not show any observable dependence on the assumption about the seasonality scenario (as reported in Additional file 1). The analysis is restricted to the first countries seeded from Mexico to preserve the conditional independence of the variables and it is natural to see the lack of any seasonal signature since these countries receive the disease from a single country, mostly found in the tropical region where no seasonal effects are expected.
In order to find the minimum seasonality scaling factor αmin that best fits the empirical data, we performed a statistical correlation analysis of the arrival time of the infection in the 93 countries infected as of 18 June, as detailed in the Methods section and Additional file 1. By considering a larger number of countries and a longer period for the unfolding of the epidemic worldwide as seasons change, the correlation analysis for the baseline scenario provides clear statistical indications for a minimum rescaling factor in the interval 0.6 < αmin < 0.7. In the full range of epidemic parameters explored, the correlation analysis yields values for αmin in the range 0.4 to 0.9. This evidence for a mild seasonality rescaling is consistent with the activity observed in the months of June and July in Europe and the US where the epidemic progression has not stopped and the number of cases keeps increasing considerably (see also Table 2 for the corresponding values of R(t) in those regions during summer months).
This analysis allows us to provide a comparison with the epidemic activity observed so far, and most importantly an early assessment of the future unfolding of the epidemics. For each set of parameters the model generates quantities of interest such as the profile of the epidemic behavior in each subpopulation or the number of imported cases. Each simulation generates a stochastic realization of the process and the curves are the statistical aggregate of at least 2 × 103 realizations. In the following we report the median profiles and where indicated the 95% CI. For the sake of clarity data are aggregated at the level of country or geographical region. Additional file 1 reports a detailed comparison of the simulated number of cases in Australia, US, UK with the reported cases from official sources in the period May to July. Results are in good agreement with the reported temporal evolution of the epidemic and highlight a progressive decrease of the monitoring activity caused by the increasing number of cases, as expected [7]. The same information is also available for each single subpopulation defined in the model. We have therefore tested the model results in four territories of Australia. Interestingly, the model is able to recover the different timing observed in the four territories. A detailed discussion of this comparison is reported in Additional file 1.
Peak times
Region | Estimated activity peak time |
|---|---|
North America | 25 September to 9 November |
Western Europe | 14 October to 21 November |
Lower South America | 30 July to 6 September |
South Pacific | 28 July to 17 September |
Daily new number of cases and epidemic sizes in several countries
Country | Peak time | New daily cases at the peak time (thousands) | New daily cases at the peak time (% of population) | Epidemic size at 15 October (% of population) | |
|---|---|---|---|---|---|
αmin 0.6 | αmin 0.7 | ||||
United States | 24 September to 9 November | 2,983 to 3,302 | 1.06 to 1.17 | 4.99 to 7.38 | 23.76 to 29.96 |
Canada | 4 October to 14 November | 331 to 373 | 1.04 to 1.17 | 2.28 to 4.56 | 16.90 to 27.41 |
United Kingdom | 9 October to 18 November | 723 to 813 | 1.21 to 1.36 | 1.77 to 4.45 | 11.11 to 27.29 |
France | 12 October to 21 November | 725 to 792 | 1.26 to 1.38 | 1.83 to 3.87 | 10.86 to 26.40 |
Germany | 11 October to 20 November | 1,162 to 1,291 | 1.43 to 1.59 | 1.02 to 2.41 | 8.57 to 26.25 |
Italy | 17 October to 23 November | 793 to 867 | 1.39 to 1.52 | 0.93 to 2.20 | 6.71 to 22.13 |
Spain | 8 October to 19 November | 492 to 536 | 1.23 to 1.34 | 2.39 to 3.70 | 13.26 to 27.95 |
China | 8 November to 11 December | 14,077 to 16,207 | 1.16 to 1.34 | 0.65 to 5.34 | 1.51 to 9.49 |
Japan | 13 October to 16 November | 1,539 to 1,822 | 1.21 to 1.43 | 1.47 to 4.86 | 5.84 to 24.65 |
Number of hospitalizations per 100,000 persons at the activity peak in several countries
HR based on seasonal influenza, 0.08% | HR based on multiplier method | HR based on WHO confirmed cases, 10% | ||
|---|---|---|---|---|
0.3% | 1% | |||
USA | 2.21 | 8.28 | 27.58 | 275.84 |
Canada | 2.18 | 8.17 | 27.22 | 272.23 |
UK | 2.52 | 9.45 | 31.52 | 315.15 |
France | 2.61 | 9.79 | 32.64 | 326.40 |
Germany | 2.98 | 11.17 | 37.22 | 372.18 |
Italy | 2.87 | 10.76 | 35.87 | 358.67 |
Spain | 2.54 | 9.54 | 31.81 | 318.12 |
China | 2.48 | 9.32 | 31.05 | 310.50 |
Japan | 2.59 | 9.70 | 32.32 | 323.19 |
Delay effect induced by the use of antiviral drugs for treatment with 30% case detection and drug administration. (a) Peak times of the epidemic activity in the worst-case scenario (black) and in the scenario where antiviral treatment is considered (red), for a set of countries in the Northern hemisphere. The intervals correspond to the 95% confidence interval (CI) of the peak time for the two values defining the best-fit seasonality scaling factor interval. (b, c) Incidence profiles for Spain and Germany in the worst-case scenario (black) and in the scenario where antiviral treatment is considered (red). Results are shown for αmin = 0.6 only, for the sake of visualization. A delay of about 4 weeks results from the implemented mitigation.
Conclusion
We have defined a Monte Carlo likelihood analysis for the assessment of the seasonal transmission potential of the new A(H1N1) influenza based on the analysis of the chronology of case detection in affected countries at the early stage of the epidemic. This method allows the use of data coming from the border controls and the enhanced surveillance aimed at detecting the first cases reaching uninfected countries. This data is, in principle, more reliable than the raw count of cases provided by countries during the evolution of the epidemic. The procedure provides the necessary input to the large-scale computational model for the analysis of the unfolding of the pandemic in the future months. The analysis shows the potential for an early activity peak that strongly emphasizes the need for detailed planning for additional intervention measures, such as social distancing and antiviral drugs use, to delay the epidemic activity peak and thus increase the effectiveness of the subsequent vaccination effort.
Notes
Declarations
Acknowledgements
The authors thank IATA and OAG for providing their databases. The authors are grateful to the Staff of the Big Red Computer and the Computational Facilities at Indiana University. The authors would like to thank Ciro Cattuto for his support with computational infrastructure at ISI Foundation. The authors are partially supported by the NIH R21-DA024259 award, the Lilly Endowment grant 2008 1639-000, the DTRA-1-0910039 grant, the ERC project EpiFor and the FET projects Epiwork and Dynanets.
Authors’ Affiliations
References
- Eubank S, Guclu H, Kumar VS, Marathe MV, Srinivasan A, Toroczkai Z, Wang N: Modelling disease outbreaks in realistic urban social networks. Nature. 2004, 429: 180-184. 10.1038/nature02541.View ArticlePubMedGoogle Scholar
- Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS: Strategies for mitigating an influenza pandemic. Nature. 2006, 442: 448-452. 10.1038/nature04795.View ArticlePubMedGoogle Scholar
- Germann TC, Kadau K, Longini IM, Macken CA: Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci USA. 2006, 103: 5935-5940. 10.1073/pnas.0601266103.View ArticlePubMedPubMed CentralGoogle Scholar
- Colizza V, Barrat A, Barthelemy M, Valleron A-J, Vespignani A: Modeling the worldwide spread of pandemic influenza: baseline case and containment interventions. PloS Medicine. 2007, 4: e13-10.1371/journal.pmed.0040013.View ArticlePubMedPubMed CentralGoogle Scholar
- Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Van Kerkhove MD, Hollingsworth TD, Griffin J, Baggaley RF, Jenkins HE, Lyons EJ, Jombart T, Hinsley WR, Grassly NC, Balloux F, Ghani AC, Ferguson NM, Rambaut A, Pybus OG, Lopez-Gatell H, Alpuche-Aranda CM, Chapela IB, Zavala EP, Guevara DM, Checchi F, Garcia E, Hugonnet S, Roth C, WHO Rapid Pandemic Assessment Collaboration: Pandemic potential of a strain of influenza A(H1N1): early findings. Science. 2009, 324: 1557-1561. 10.1126/science.1176062.View ArticlePubMedPubMed CentralGoogle Scholar
- Cruz-Pacheco G, Duran L, Esteva L, Minzoni A, Lopez-Cervantes M, Panayotaros P, Ahued Ortega A, Villasenor Ruiz I: Modelling of the influenza A(H1N1)v outbreak in Mexico City, April-May 2009, with control sanitary measures. Euro Surveill. 2009, 14: 19254.PubMedGoogle Scholar
- World Health Organization: Pandemic (H1N1) 2009 briefing note 3 (revised): changes in reporting requirements for pandemic (H1N1) 2009 virus infection. [http://www.who.int/csr/disease/swineflu/notes/h1n1_surveillance_20090710/en/index.html]
- Khan K, Arino J, Hu W, Raposo P, Sears J, Calderon F, Heidebrecht C, Macdonald M, Liauw J, Chan A, Gardam M: Spread of a novel influenza A(H1N1) virus via global airline transportation. N Engl J Med. 2009, 361: 212-214. 10.1056/NEJMc0904559.View ArticlePubMedGoogle Scholar
- Anderson RM, May RM: Infectious diseases in humans. 1992, Oxford, UK: Oxford University PressGoogle Scholar
- Balcan D, Colizza V, Gonçalves B, Hu H, Ramasco JJ, Vespignani A: Multiscale mobility networks and the large scale spreading of infectious diseases. arXiv. 2009, 0907.3304.Google Scholar
- Boelle PY, Bernillon P, Desenclos JC: A preliminary estimation of the reproduction ratio for new influenza A(H1N1) from the outbreak in Mexico, March-April 2009. Euro Surveill. 2009, 14: 19205.PubMedGoogle Scholar
- Nishiura H, Castillo-Chavez C, Safan M, Chowell G: Transmission potential of the new influenza A(H1N1) virus and its age-specificity in Japan. Euro Surveill. 2009, 14: 19227.PubMedGoogle Scholar
- Nishiura H, Wilson NM, Baker MG: Estimating the reproduction number of the novel influenza A virus (H1N1) in a Southern Hemisphere setting: preliminary estimate in New Zealand. NZ Med J. 2009, 122: 1-5.Google Scholar
- Rvachev LA, Longini IM: A mathematical model for the global spread of influenza. Math Biosci. 1985, 75: 3-22. 10.1016/0025-5564(85)90064-1.View ArticleGoogle Scholar
- Grais RF, Hugh Ellis J, Glass GE: Assessing the impact of airline travel on the geographic spread of pandemic influenza. Eur J Epidemiol. 2003, 18: 1065-1072. 10.1023/A:1026140019146.View ArticlePubMedGoogle Scholar
- Hufnagel L, Brockmann D, Geisel T: Forecast and control of epidemics in a globalized world. Proc Natl Acad Sci USA. 2004, 101: 15124-15129. 10.1073/pnas.0308344101.View ArticlePubMedPubMed CentralGoogle Scholar
- Cooper BS, Pitman RJ, Edmunds WJ, Gay N: Delaying the international spread of pandemic influenza. PloS Medicine. 2006, 3: e12-10.1371/journal.pmed.0030212.View ArticleGoogle Scholar
- Epstein JM, Goedecke DM, Yu F, Morris RJ, Wagener DK, Bobashev GV: Controlling pandemic flu: the value of international air travel restrictions. PLoS ONE. 2007, 2: e401-10.1371/journal.pone.0000401.View ArticlePubMedPubMed CentralGoogle Scholar
- Flahault A, Vergu E, Coudeville L, Grais R: Strategies for containing a global influenza pandemic. Vaccine. 2006, 24: 6751-6755. 10.1016/j.vaccine.2006.05.079.View ArticlePubMedGoogle Scholar
- Viboud C, Bjornstad O, Smith DL, Simonsen L, Miller MA, Grenfell BT: Synchrony, waves, and spatial hierarchies in the spread of influenza. Science. 2006, 312: 447-451. 10.1126/science.1125237.View ArticlePubMedGoogle Scholar
- Flahault A, Valleron A-J: A method for assessing the global spread of HIV-1 infection based on air travel. Math Popul Stud. 1991, 3: 1-11.View ArticleGoogle Scholar
- Colizza V, Barrat A, Barthélemy M, Vespignani A: The role of airline transportation network in the prediction and predictability of global epidemics. Proc Natl Acad Sci USA. 2006, 103: 2015-2020. 10.1073/pnas.0510525103.View ArticlePubMedPubMed CentralGoogle Scholar
- Socioeconomic Data and Applications Center (SEDAC), Columbia University. [http://sedac.ciesin.columbia.edu/gpw]
- International Air Transport Association. [http://www.iata.org]
- Official Airline Guide. [http://www.oag.com/]
- Barrat A, Barthélemy M, Pastor-Satorras R, Vespignani A: The architecture of complex weighted networks. Proc Natl Acad Sci USA. 2004, 101: 3747-3752. 10.1073/pnas.0400087101.View ArticlePubMedPubMed CentralGoogle Scholar
- Okabe A, Boots B, Sugihara K, Chiu S-N: Spatial Tessellations - Concepts and Applications of Voronoi Diagrams. 2000, John Wiley, 2View ArticleGoogle Scholar
- Keeling MJ, Rohani P: Estimating spatial coupling in epidemiological systems: a mechanistic approach. Ecol Lett. 2002, 5: 20-29. 10.1046/j.1461-0248.2002.00268.x.View ArticleGoogle Scholar
- Sattenspiel L, Dietz K: A structured epidemic model incorporating geographic mobility among regions. Math Biosci. 128: 71-91. 10.1016/0025-5564(94)00068-B.Google Scholar
- Longini IM, Halloran ME, Nizam A, Yang Y: Containing pandemic influenza with antiviral agents. Am J Epidemiol. 2004, 159: 623-633. 10.1093/aje/kwh092.View ArticlePubMedGoogle Scholar
- Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, Leach S, Valleron AJ: Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol. 2008, 167: 775-785. 10.1093/aje/kwm375.View ArticlePubMedGoogle Scholar
- Longini IM, Nizam A, Xu S, Ungchusak K, Hanshaoworakul W, Cummings DAT, Halloran ME: Containing pandemic influenza at the source. Science. 2005, 309: 1083-1087. 10.1126/science.1115717.View ArticlePubMedGoogle Scholar
- Brote de infeccion respiratoria aguda en La Gloria, Municipio de Perote, Mexico. Secretaria de Salud, Mexico. [http://portal.salud.gob.mx/contenidos/noticias/influenza/estadisticas.html]
- World Health Organization: WHO Weekly. Epidemiol Rec. 2009, 84: 197-202.Google Scholar
- CDC Interim guidance for clinicians on identifying and caring for patients with swine-origin influenza A(H1N1) virus infection (2009). [http://www.cdc.gov/h1n1flu/identifyingpatients.htm]
- Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, Gubareva LV, Xu X, Bridges CB, Uyeki TM: Emergence of a Novel Swine-origin Influenza A(H1N1) Virus in Humans. N Engl J Med. 2009, 360: 2605-2615. 10.1056/NEJMoa0903810.View ArticleGoogle Scholar
- Roberts MJ, Heesterbeek JAP: Model-consistent estimation of the basic reproduction number from the incidence of an emerging infection. J Math Biol. 2007, 55: 803-816. 10.1007/s00285-007-0112-8.View ArticlePubMedPubMed CentralGoogle Scholar
- Wallinga J, Lipsitch M: How generation intervals shape the relationship between growth rates and reproductive numbers. Proc R Soc B. 2007, 274: 599-604. 10.1098/rspb.2006.3754.View ArticlePubMedGoogle Scholar
- Gani R, Hughes H, Fleming D, Griffin T, Medlock J, Leach S: Potential impact of antiviral drug use during influenza pandemic. Emerg Infect Dis. 2005, 11: 1355-1362.View ArticlePubMedPubMed CentralGoogle Scholar
- Elveback LR, Fox JP, Ackerman E, Langworthy A, Boyd M, Gatewood L: An influenza simulation model for immunization studies. Am J Epidemiol. 1976, 103: 152-165.PubMedGoogle Scholar
- Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DA: Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009, 9: 291-300. 10.1016/S1473-3099(09)70069-6.View ArticlePubMedPubMed CentralGoogle Scholar
- Mills CE, Robins JM, Lipsitch M: Transmissibility of 1918 pandemic influenza. Nature. 2004, 432: 904-906. 10.1038/nature03063.View ArticlePubMedGoogle Scholar
- Wilson N, Baker MG: The emerging influenza pandemic: estimating the case fatality ratio. Euro Surveill. 2009, 14: 19255.PubMedGoogle Scholar
- Garske T, Legrand J, Donnelly CA, Ward H, Cauchemez S, Fraser C, Ferguson NM, Ghani AC: Assessing the severity of the novel A/H1N1 pandemic. BMJ. 2009, 339: b2840-10.1136/bmj.b2840.View ArticlePubMedGoogle Scholar
- Novartis successfully demonstrates capabilities of cell-based technology for production of A(H1N1) vaccine. [http://www.novartis.com/newsroom/media-releases/en/2009/1322241.shtml]
- CDC: Novel H1N1 influenza vaccine. [http://www.cdc.gov/h1n1flu/vaccination/public/vaccination_qa_pub.htm]
- Ferguson NM, Cummings DA, Cauchemez S, Fraser C, Riley S, Meeyai A, Iamsirithaworn S, Burke DS: Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature. 2005, 437: 209-214. 10.1038/nature04017.View ArticlePubMedGoogle Scholar
- Germann TC, Kadau K, Longini IM, Macken CA: Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci USA. 2006, 103: 5935-5940. 10.1073/pnas.0601266103.View ArticlePubMedPubMed CentralGoogle Scholar
- Arinaminpathy N, McLean AR: Antiviral treatment for the control of pandemic influenza: some logistical constraints. J R Soc Interface. 2008, 5: 545-553. 10.1098/rsif.2007.1152.View ArticlePubMedGoogle Scholar
- Wu JT, Riley S, Fraser C, Leung GM: Reducing the impact of the next influenza pandemic using household-based public health interventions. PLoS Med. 2006, 3: e361-10.1371/journal.pmed.0030361.View ArticlePubMedPubMed CentralGoogle Scholar
- Roche: update on current developments around Tamiflu. [http://www.roche.com]
- Singer AC, Howard BM, Johnson AC, Knowles CJ, Jackman S, Accinelli C, Caracciolo AB, Bernard I, Bird S, Boucard T, Boxall A, Brian JV, Cartmell E, Chubb C, Churchley J, Costigan S, Crane M, Dempsey MJ, Dorrington B, Ellor B, Fick J, Holmes J, Hutchinson T, Karcher F, Kelleher SL, Marsden P, Noone G, Nunn MA, Oxford J, Rachwal T, et al: Meeting report: risk assessment of Tamiflu use under pandemic conditions. Environ Health Perspect. 2008, 116: 1563-1567.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1741-7015/7/45/prepub
Pre-publication history
Copyright
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


